{
    "nct_id": "NCT06120491",
    "official_title": "A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)",
    "inclusion_criteria": "* Male ≥ 18 years of age.\n* Histologically documented prostate adenocarcinoma which is de novo or recurrent and castration-sensitive. Participants with pathologic features of small cell, neuroendocrine, sarcomatoid, spindle cell, or signet cell histology are not eligible.\n* Metastatic disease as documented by the investigator prior to randomisation, with clear evidence of ≥ 1 bone lesion and/or ≥ 1 soft tissue lesion that is suitable for repeated assessment with CT and/or MRI.\n* Participant is receiving ADT with a GnRH analogue or has undergone bilateral orchiectomy starting ≥ 14 days and < 4 months prior to randomisation.\n* ECOG performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomisation.\n* Provision of FFPE tumour tissue sample and blood sample (for ctDNA).\n* Confirmed HRRm status by central tumour tissue and/or ctDNA test is required to determine cohort eligibility.\n* Adequate organ and bone marrow function as described in study protocol.\n* Participants must not father children or donate sperm from signing ICF, during the study intervention and for 6 months after the last dose of study intervention.\n* Participants must use a condom from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "* Participants with a history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). In case there is no clinical MDS/AML suspicion, no specific screening for MDS/AML (by BM/bone biopsy) is required.\n* Participants with any known predisposition to bleeding.\n* Any history of persisting (> 2 weeks) severe cytopenia.\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305 and/or the assigned NHA.\n* History of another primary malignancy, with exceptions.\n* Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anticancer therapy.\n* Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.\n* Cardiac criteria, including history of arrhythmia and cardiovascular disease.\n* Any prior anticancer pharmacotherapy or surgery for metastatic prostate cancer, with exceptions.\n* Prior treatment within 14 days with blood product support or growth factor support.\n* Participants who are unevaluable for both bone and soft tissue progression.",
    "miscellaneous_criteria": ""
}